ERBB2 and cancer: We found several prospective clinical trials evaluating the efficacy of HER2-targeted ADCs in patients with cancer which also involved the investigation on adverse events, however, there is no systematic review and meta-analysis for comprehensive summary of treatment-related adverse events associated with HER2-targeted ADCs except the single drug T-DM1.